{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:05:14Z","timestamp":1784696714321,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aplastic anemia (AA) is a bone marrow failure syndrome. Whether the combination of TPO-RAs and IST is superior to IST alone is an ongoing debate. This meta-analysis compares the efficacy of EPAG+IST versus IST alone, and assesses the initiation timing and treatment duration of eltrombopag (EPAG) across different age groups of AA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The literature was retrieved from Chinese and English databases up to October 1, 2025. The analysis was conducted using RevMan 5.4 software, employing a fixed-effects model to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the outcomes. The\n                      <jats:italic>I\u00b2<\/jats:italic>\n                      statistic was used to assess heterogeneity among included studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>21 studies involving 2,239 patients were included. The overall response rate in the EPAG+IST group was higher at 3 months (OR = 2.13, 95% CI 1.65 \u2013 2.74, P &amp;lt; 0.00001) and 6 months (OR = 2.13, 95% CI 1.73 \u2013 2.61, P &amp;lt; 0.00001). There was no significant difference between the two groups at 12 months (OR = 1.14, 95% CI 0.86 \u2013 1.51, P = 0.36, I\u00b2 = 35%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The addition of EPAG to IST may improve early hematological responses at 3 and 6 months in patients with AA, with no significant difference at 12 months. Concurrent initiation (within 7 days) was associated with earlier responses in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42024604778\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1766549","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:40:08Z","timestamp":1784695208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuai","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhan","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaochi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, National Clinical Research Center for Geriatric Diseases, Capital Medical University (XWH-CMU)","place":["Beijing, China"]},{"name":"Comprehensive Center for Neuro-oncology, Xuanwu Hospital, Capital Medical University (XWH-CMU)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/asheducation-2013.1.76","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"2013","author":"Young","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1413485","article-title":"Aplastic anemia","volume":"379","author":"Young","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169862","article-title":"Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011","volume":"102","author":"Vaht","year":"2017","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22214.1","article-title":"Novel therapeutic choices in immune aplastic anemia","volume":"9","author":"Scheinberg","year":"2020","journal-title":"F1000Research"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31658","article-title":"Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04966-w","article-title":"A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia","volume":"101","author":"Jin","year":"2022","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2021.1895924","article-title":"Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: a Chinese retrospective study","volume":"38","author":"Fang","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"key":"B13","first-page":"28","article-title":"Effects of eltrombopag combined with intensive immunosuppression in treatment of patients with aplastic anemia","volume":"35","author":"Fang","year":"2023","journal-title":"Med J Chin Peoples Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17232","article-title":"Eltrombopag added to immunosuppression for children with treatment-na\u00efve severe aplastic anaemia","volume":"192","author":"Groarke","year":"2021","journal-title":"Br J Haematol"},{"key":"B15","volume-title":"Eltrombopag added to standard immunosuppressive therapy in Chinese patients with very severe or severe aplastic anemia: efficacy, safety, and prognostic assessment","author":"Hu","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2021.1900475","article-title":"Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children","volume":"38","author":"Jie","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"key":"B17","article-title":"Effect of eltrombopag on response to immunosuppressive therapy in patients with transfusion-dependent non-severe aplastic anemia","volume":"31","author":"Lin","year":"2023","journal-title":"J Exp Hematol"},{"key":"B18","article-title":"Effects of eltrombopag combined with cyclosporine A on serum thrombopoietin, granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in patients with aplastic anemia","volume":"42","author":"Yang","year":"2021","journal-title":"World Clin Drug"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006716","article-title":"Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia","volume":"7","author":"Goronkova","year":"2023","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29066","article-title":"Eltrombopag in children with severe aplastic anemia","volume":"68","author":"Lesmana","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.9.1130","article-title":"Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome","volume":"289","author":"Rosenfeld","year":"2003","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v96.6.2049","article-title":"Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia","volume":"96","author":"Kojima","year":"2000","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07450.x","article-title":"Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia","volume":"144","author":"Scheinberg","year":"2009","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15650","article-title":"The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of adolescents and young adults with children and older adults","volume":"183","author":"Cabannes-Hamy","year":"2018","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278413","article-title":"Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag","volume":"107","author":"Zaimoku","year":"2021","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01378.x","article-title":"Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia","volume":"84","author":"Chang","year":"2010","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03670-3","article-title":"Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia","volume":"118","author":"Shinn","year":"2023","journal-title":"Int J Hematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood.2021012130","article-title":"Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study","volume":"139","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2022.08.001","article-title":"Clonality in immune aplastic anemia: mechanisms of immune escape or Malignant transformation","volume":"59","author":"Durrani","year":"2022","journal-title":"Semin Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01636-8","article-title":"Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia","volume":"36","author":"Groarke","year":"2022","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood-2020-141375","article-title":"Long-term eltrombopag for bone marrow failure depletes iron","volume":"97","author":"Young","year":"2022","journal-title":"Am J Hematol"},{"key":"B32","article-title":"Efficacy analysis of eltrombopag combined with cyclosporine in the treatment of aplastic anaemia","volume":"18","author":"Cai","year":"2021","journal-title":"J North Pharm"},{"key":"B33","article-title":"Eltrombopag combing with intensive immunosuppressive therapy for elderly severe aplastic anemia: clinical analysis of 35 cases","volume":"41","author":"Chai","year":"2021","journal-title":"Chin J Pract Intern Med"},{"key":"B34","article-title":"Effect of eltrombopag on clinical efficacy and safety in patients with chronic aplastic anaemia","volume":"33","author":"Liang","year":"2023","journal-title":"Shenzhen J Integr Tradit Chin West Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04401-6","article-title":"Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series","volume":"100","author":"Martynova","year":"2021","journal-title":"Ann Hematol"},{"key":"B36","unstructured":"The efficacy of immunosuppression combined with Eltrombopag in the treatment of severe aplastic anemia in children\n          \n          \n            \n              Zhang\n              Y\n            \n            \n              Liu\n              M\n            \n            \n              Zhan\n              X"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1095143","article-title":"Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia","volume":"10","author":"Zhao","year":"2023","journal-title":"Front Pediatr"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:40:24Z","timestamp":1784695224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1766549"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1766549","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1766549"}}